Condition
Stage IIIA Esophageal Adenocarcinoma
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
66.7%
2 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
2 of 0 completed with results
Key Signals
2 with results0
Data Visualizations
Phase Distribution
3Total
P 2 (2)
P 4 (1)
Trial Status
Terminated2
Suspended1
Clinical Trials (3)
Showing 3 of 3 trials
NCT02366819Phase 4Suspended
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
NCT02234180Phase 2Terminated
Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery
NCT02392377Phase 2Terminated
Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal Cancer Receiving Combination Chemotherapy
Showing all 3 trials